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This article  presents  a framework  to evaluate  holistically  the  operational  and  economic  performance  of
different  manufacturing  platforms  for the  expansion  of  allogeneic  mesenchymal  stromal  cells  (MSCs)
across  different  commercialisation  scenarios.  The  tool  comprised  models  for whole  bioprocess  eco-
nomics  linked  to uncertainty  analysis,  dynamic  scheduling,  brute-force  optimisation  and  multi-attribute
decision-making.  The  tool  was  used  to determine  the cost  of  goods  (COG),  robustness,  operational  ease
and  business  feasibility  of competing  cell culture  technologies  under  different  scale, demand,  reimburse-
ment  and  dose  size  scenarios,  and  to  determine  the performance  improvements  required  for  commercial
success.  The  results  revealed  that  in  low  annual  demand  (10 billion  cells/year)  scenarios,  multi-plate
bioreactors  have  superior  operational  and  economic  characteristics.  At  larger  annual  demands  (10  tril-
lion cells/year),  however,  the  tool  predicts  that microcarrier-based  bioreactors  are  optimal  due  to  theireimbursement
ulti-attribute decision-making analysis
relative cost-effectiveness  and  operational  beneﬁts  conferred  by  their  closed  and  controlled  characteris-
tics  that  outweigh  the uncertainties  associated  with  their  use.  Moreover,  whilst  further  analysis  of  high
dose,  high  demand  (1 billion  cells/dose,  10,000  doses/year)  scenarios  has  shown  that  signiﬁcant  improve-
ment in  the performance  of  cell  culture  processes  may  result  in  satisfactory  COG,  current  limitations  in
the capacity  of  downstream  processing  (DSP)  technologies  may  not  allow  full  market  capture.
© 2018  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Cell therapy products have been proposed as a novel approach
or treatment and possibly cure of a number of chronic indications.
owever, these therapeutics present signiﬁcant challenges that
nclude high COG, high process variability and scale-up restrictions
1–6]. As COG decreases with increasing manufacturing scale [7],
here is an increased interest in the development and evaluation of
calable technologies for cell therapy manufacture. Methods for the
valuation of novel technologies are often based on COG and pro-
ess yield. However, there are a number of less tangible issues that
ust also be considered when designing a manufacturing processor cell therapy products such as robustness, biological limitations,
echnology scalability, and ease of development. This paper aims at
roviding a holistic approach to evaluate the beneﬁts of different
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technologies for the manufacture of adherent cells that captures
economic aspects (e.g. COG, ﬁxed capital investment, reimburse-
ment potential) as well as operational aspects (e.g. robustness,
resource requirement, ease of validation, ease of operation, ease
of development).
The cell therapy market was  estimated at $12 billion USD  in
2016 and is estimated to grow at a CAGR of 31.1% to $61 billion
USD by 2022 [8]. The global market for mesenchymal stem cells
(MSCs) alone is foreseen to reach $7.5 billion USD  by 2022 with the
United States having the largest share of this market (34.3%) and
Asia being the continent with the highest projected CAGR (14.1%)
[9].
Mesenchymal stem cells also referred to as mesenchymal stro-
mal  cells were ﬁrst identiﬁed by Friedenstein and colleagues [10]
as post-natal cells that are capable of self-renewal and differen-
tiation [11–14] into other cells such as cardiomyocytes, neurons
and insulin producing cells. This potency of MSCs makes them
suitable for the treatment of diseases such as cardiovascular dis-
eases, spinal cord injury, Parkinson’s and diabetes [15–20]. MSCs
can be retrieved from multiple sources such as the bone marrow,
adipose tissue, amniotic ﬂuid, dental tissues, peripheral blood, and
placenta [14,21–26]. Beneﬁts to the use of MSCs include the fact
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Nomenclature
Nnunit Number of cell culture vessels required for the
expansion stage n0
Ncells/batch Number of cells produced per batch
yDSP DSP yield
ycell detachment Cell detachment yield
ybatch sucess Batch success rate
at Surface area for cell growth of a cell culture vessel
Densitymicrocarrier Microcarrier’s seeding density
Utilisationcell culture vessel % utilization a cell culture vessel
aper gram Surface area per gram of microcarrier
Cmedia Media costs
Cmedia/ml Media costs per ml
Vmedia/a Volume of media required per unit surface are of cell
culture vessel
Ctrypsin Trypsin costs
Ctrypsin/ml Trypsin costs/ml
Vtrypsin/a Volume of trypsin required per unit surface are of
cell culture vessel
Cconsumables Consumables costs
Cconsumable/unit Consumables costs per cell culture vessel
Clabour Labour costs
Coperator Operator salary
Rdocumentation/executing Ratio between the documentation
operator and the executing operator
ROverhead/operator Ratio between labour overheads and oper-
ator salary
tstep Time required per cell culture vessel to perform a
particular activity
tstepmax Maximum time allowed for a particular activity
FCI Fixed capital investment
Cequipment Equipment costs
Lf Lang factor
Cequipmnet/unit Unit costs for a particular type of equipment
Capacityequipment Max  number of cell culture vessels that the
equipment can handle
C Biosafety cabinet costs
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CBSC/unit Biosafety cabinet costs per unit
hat they have a low half-life [27], low immunogenicity [28–29] and
mmunomodulatory characteristics, making these cells suitable for
he treatment of graft vs host disease (GvHD), rheumatoid arthritis
nd Alzheimer’s among other indications [30–36]. MSCs have also
aracrine and homing properties [27,37]. Given the many bene-
cial characteristics of MSCs, these have now been used in over
00 clinical trials across multiple indications [1,27,37–40]. To date,
ommercialised MSC  cell therapy products include Heartcelligram-
MI
®
(Pharmicell, South Korea), Prochymal
®
(Osiris, MD,  USA)
nd Cartistem
®
(Medipost, Weymouth, UK). The key information
egarding these therapies and other therapies is summarised in
able 1. The COG and reimbursement potential of MSC-based prod-
cts targeting some of these indications will be explored in this
rticle. The success of the few commercially available cell therapy
roducts has been accompanied by some high-proﬁle failures. Rea-
ons for these failures include high COG, failure to demonstrate
ufﬁcient clinical beneﬁt and low market penetration due to price
nd competition [7,41–45].
Although allogenic cell therapy products have the potential to
e more cost-effective than autologous products [38,41], as their
roduction can be scaled-up as opposed to scaled-out [47], these
roducts must still overcome a number of regulatory, scientiﬁc
nd manufacturing hurdles in order to achieve commercial success
45–48]. The limited scalability of technologies for the manufactureineering Journal 137 (2018) 132–151 133
of anchorage-dependent cells is one of the key challenges associ-
ated with designing a process for commercial scale manufacture
of MSC-based products [34,48,49]. The severity of this scalability
issue depends on the indication being targeted [50]. For low dose
indications (∼1 × 107 cells) such as chronic low back pain [50,51],
multilayer ﬂasks may  sufﬁce for cell culture; these ﬂasks have the
adequate capacity to produce cell numbers as high as 400 billion
cells per batch [53]. Multi-layer ﬂasks employ open processing and
hence require cleanrooms with high ISO qualiﬁcations [54] that
can increase the initial facility investment required, which may  be
cost-prohibitive for some SMEs. For treatments such as GvHD or
heart disease with higher dose sizes (∼107–108 cells) [28,55–58]
however, larger manufacturing scales would be required. Larger
manufacturing scales require the use of bioreactors with microcar-
riers which will allow for batch sizes as high as 1 trillion cells to be
achieved [39,52], while maintaining optimal and controlled physio-
chemical conditions and environment growth for cell growth [59].
The use of microcarriers in suspension carries its own hurdles that
include achieving consistent performance upon scale-up [60] and
that the cells must be separated from the microcarriers after the
cell culture step [1,53]. Cell separation is typically carried out using
enzymatic intervention [61], which must be quenched rapidly to
avoid damage to the cells [2]. The time between cell detachment
and ﬁnal formulation typically varies from less than 1 h [2,62] to
4 h [63]. Moreover, there are a number of different microcarriers
available on the market which would yield different attachment
efﬁciencies, proliferation rates and have different effects on the
pluripotency of the cells [53,64,65] (Table 2). Alternative bioreac-
tors for adherent cell expansion include the Quantum
®
hollow ﬁbre
(Terumo BCT, Lakewood, CA, USA) [7,53,66–69] and the Xpansion
®
(Pall Life Sciences, NY, USA) [7,53,70–72]. Both technologies, offer a
closed and controlled environment for cell growth, however these
offer lower capacity than microcarrier-based cell therapy [7]. This
article will establish the economic and operational trade-offs asso-
ciated with both planar and microcarrier-based cell culture.
Increasing the scale of manufacture also decreases the number
of feasible candidate technologies for wash and concentration of
cell therapy products [63]. One of the most promising technologies
on the market for cell harvest and wash is the tangential ﬂow ﬁl-
tration (TFF) system previously used in the biopharma industry for
protein puriﬁcation and adapted to cell therapy products by differ-
ent companies [73]. The drawback associated with the use of this
technology is that the TFF process may  sometimes be stressful to the
cells [62]. A second alternative to large scale wash and concentra-
tion of cell therapy products is the use of ﬂuidised bed centrifuges
such as kSep
®
(Sartorius, Göttingen, Germany) [63]; this technology
is able to process batch sizes as high as 1000 L [73] with a capacity
of 0.6 trillion cells per cycle [74]. Fill and cryopreservation are also
a bottleneck at scale. Thousands of doses per batch can be vialled
using the Crystal
®
PX Filling Line (Aseptic Technologies, Gembloux,
Belgium) [63,73].
Cell therapy products are complex, very sensitive to environ-
mental changes and require multiple expensive biological agents
[5]. Moreover, as previously mentioned, the current cell therapy
manufacturing process is highly manual, which makes an already
expensive process highly variable and susceptible to operator
error [3]. The chances for operator error are bound to increase
with increasing batch size as more manipulations are required.
Additional sources of variability are encountered in cell ther-
apy manufacturing. These sources include: the cell source, age
and health of the donor, the heterogeneity of the cell bank and
reagents such as the serum batch [1–4,27,37,40]. Process variability
is an important factor to be considered when selecting a manu-
facturing platform and this article will explore its effect on the
cost-effectiveness of different technologies. Strategies to decrease
donor-related variability includes donor screening.
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Table 1
Current cell therapy products available on the market. Auto = autologous, Allo = allogeneic.
Product name Product
developerw
Indication Type Dose size Cell type Selling price/dose Country
Allostem® Allosource Bone repair [94] Allo [94] 6.63 K cells/ml [94] Adipose MSC  [94] $540–$3,500
(1 ml–10ml) [94]
US
Apligraft® Organogenisis Chronic wounds[95] Allo [95] 44 cm2 [96] Keratinocytes &
Neonatal
Fibroblasts [95]
$21.22 cm2 [97] US/Saudi Arabia
BioDfactor® BioDlogics Tissue repair [98] Allo [99] 0.25 ml–1.25 ml
[99]
Placenta cells [99] – US
BioDfence® BioDlogics Tissue repair [98] Allo [99] 3 cm2–12 cm2 [99] Placenta cells [99] – US
CardioRel® Reliance life sciences Myocardial infraction
[100]
Auto [100]  – MSCs [100] – India
Carticel® Genzyme Cartilage repair [101] Auto [101] 0.6–3.3 M cells/cm2
[101]
Chrondocytes [101] $13,300–15,000 [102] US/EU
Cartistem® Medipost Osteoarthritis [103] Allo [104] 2.5 M cells/cm2
[105]
UC Mesenchymal
cells [105]
$20,000–$40,000 [106] South Korea
Chrondocelect® TiGenix Cartilage repair
[107]
Auto [107] 0.4 ml/vial Cartilage cells
[107]
$24,000 [106] EU (withdrawn)
(100 B cells/ml)
[107]
Cupistem® Anterogen Rectal ﬁstula [108] Auto [109] – Adipose [108]  – South Korea
Dermagraft® Organogenisis Chronic wounds [110] Allo [111] 37.5 cm2 [112] Fetal Fibroblasts
[110]
$1,406 [112] US/ Canada
DeNovo  NT® Zimmer Cartilage repair [113] Allo [113] 2.5 cm2/packet
[114]
Juvenile
chondrocytes [113]
$1,440/packet [113] North America
Epicel® Genzyme Burns treatment [115] Auto [115] 50 cm2/gauze [116] Keratinocytes [116] $6,000–$10,000 per 1%
of total body surface
area [117]
US/EU
Graﬁx® Osiris Chronic wounds [118] Allo [118] – Placental cells
[118]
– US
Gintuit® Organogenesis Mucogingival
conditions [119]
Allo [119] 177 cm2 cellular
sheet with 4Mcells
[119]
Keratinocytes [119] – US
Heartcelligram-AMI® Pharmicell Post-acute myocardial
infraction [120]
Auto [120] – BM MSC  [120] $19,000 [90] South Korea
Heartsheet® Terumo Heart failure [121] Auto [121] 5 sheets [121] Skeletal myoblasts
[121]
$120,000 [106] Japan
3  × 0.1 ml/linear
cm [122]
MACI® Genzyme Cartilage repair
[123]
Auto [123] 0.5–1 M cells/sqcm of
cellular sheet [123]
Chondrocytes
[123]
– EU (suspended)
US
Orcel® Ortec Burns [124] Allo [124] – Keratinocytes,
ﬁbroblasts [124]
$27.8/cm2 [125] US
Osteoplus® Nuvasive Bone repair [126] Allo [126] 50 K cells/ml [127] MSCs [127] $460–$5,400 (1–15 ml)
[94]
US
Prochymal® Osiris GvHD [128] Allo [129] 2M cells/kg [128] BM-MSCs [129] $20,000/dose [106] Canada & New Zealand
Provenge® Dendreon Prostate cancer [130] Auto [130] 50M cells/vial
[130]
CD54 + cells [130]  $31,000/infusion (3
infusions) [131]
US
Recell® Avita medical Skin loss, scaring and
depigmentation after
burn injury [132]
Auto [132] 1 pack/320 cm2
[132]
Skin cells [132] £950 + VAT/pack [132] EU, UK, Canada, Australia
ReliNethra® Reliance life sciences Sight loss [133] Auto [133] 4 cm2/graft [133] Epithelia cells
[133]
– India
Temcell® Mesoblast GvHD [91] Allo [91] 1.2–1.7B cells [91] MSC  [91]  $7,079/72 M cells [91] Japan
Transcyte® Organogenisis Temporary would
healing [134]
Allo [134] – Fibroblasts [134] $11.75 cm2[135] US
Trinity/Trinity evolution® Orthoﬁx Bone repair [136] Allo [136] >1 K cells/ml [94] MSC  [94]  $540–$5,455 for
(1–15 ml) [94]
US
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Table  2
Examples of microcarriers currently available on the market.
Name Manufacturer Type Surface Interaction type Surface area
(cm2/g)
Working
concentration (g/L)
Average
cm2/L
Cultispher-S Sigma-Aldrich Porous Gelatin [137] Porcine Gelatin [138] 7,500 [138] 1-3 [139, 140, 141,
142]
15,000
Cytophore 1 Pharmacia Macroporous Cross-linked cotton
cellulose [65]
Diethylaminoethyl
[65,138]
11,000 [65] 2 [65, 138] 22,000
Cytophore 2 Pharmacia Macroporous 11,000 [65] 2 [65,138] 22,000
Cultispher-G Sigma-Aldrich Porous Gelatin [137, 65] Gelatin [65,138] 40,000 [65] 1-8.5 [140, 65, 143] 180,000
Cytodex 3 GE Healthcare Microporous Dextran, Gelatin
[137,138]
Denatured collagen [65,
138, 144]
2,700 [65,138] 0.5-5 [145, 65, 141,
144, 142]
Cytodex 1 GE Healthcare Porous Dextran, positively
charged [137, 138]
Diethylaminoethyl [65,
138]
4,400 [65, 146, 144] 1.2-5 [65, 146,  143,
144]
13,860
DE53 Whatman Non-Porous Cellulose [65] Diethylaminoethyl [65] 6,800 [65] 4 [65] 27,200
DE52  Whatman Non-Porous Cellulose [65] Diethylaminoethyl [65] 6,800 [65] 4 [65] 27,200
QA52  Whatman Non-Porous Cellulose [65] Quaternary Ammonium
[65]
6,800 [65] 4 [65] 27,200
CM52 Whatman Non-Porous Cellulose [65] Carboxymethyl [65] 6,800 [65] 4 [65] 27,200
Typopearl Toshbiosciences Non-Porous Hydroxylated
Methacrylate [65]
Tresyl ligand derivatized
with Protamine sulfate [65]
42,00 [65] 1 [65] 4,200
TSKge1 Toshbiosciences Non-Porous Hydroxylated
Methacrylate [65]
Tresyl ligand derivatized
with Protamine sulfate [65]
9,000 [65] 0.2 [65] 1,800
Hillex  II Pall Solohil Non-Porous Dextran, surface Modiﬁed Polystyrene,
odiﬁe
imeth
515 [147] 10-50 [147, 138] 15,450
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As seen with products such as Provenge
®
, in addition to the
anufacturing uncertainties it is very challenging to estimate the
arket penetration for novel cell therapy products. Furthermore,
redicting suitable selling prices for cell therapy products is also
 challenge at present as some of these therapies may replace the
eed for transplants, which can be priced at $600,000 USD [75], or
ven target spinal cord injury whose treatment is currently priced
t $500,000 USD to $3M USD per patient [76].
In light of such questions and uncertainties, it is evident that
osts are only one aspect to be considered when constructing a fea-
ible business plan for a novel cell therapy product, as cell therapy
roduction requires considerably more ﬂexibility and considera-
ion than the traditional biopharma products.
A limited number of publications exist on the topic of pro-
ess economics for MSC-based cell therapy products. These include
alik [42] who evaluated the relative cost-effectiveness of allo-
eneic MSC  products with respect to autologous MSC  products.
imaria et al. [7], Hassan et al. [63] and Pereira Chilima et al.
77] provided more detailed analyses of the COG of allogeneic
SC  products with the creation of models that capture mass bal-
ncing, equipment sizing, bioprocess economics and optimisation
lgorithms. The tools were used to predict the optimal technolo-
ies to be employed in upstream and downstream operations
cross different commercialisation scenarios and identify the lim-
ts of current technologies as well as the additional development
equired for these to fulﬁl future market demands. Hassan et al.
78] extended the work to provide a tool for assessing the ﬁnancial
mplications of switching to microcarrier-based cell culture at dif-
erent stages of process development considering the total cost of
evelopment as well as the overall proﬁtability. This was  achieved
y exploring the impact of different stakeholder perspectives on
he optimal process change scenario. These articles have provided
seful insights on COG and current limitations of technologies for
ell therapy manufacture; however, they have not considered the
ore qualitative operational characteristics of these technologies.
Methods to combine less tangible operational features with
uantitative economic features for a more holistic analysis include
he use of multi-attribute decision-making (MADM), stochastic
nalysis and resource requirement analysis. These techniques have
reviously been used for protein biopharmaceuticals such as mon-
clonal antibodies (mAbs) in order to address questions such as thed with cationic
ylammonium [138]
beneﬁt of single use vs stainless steel technologies as well as the
beneﬁt of fed-batch vs perfusion cell cultures [79,80]. In cell ther-
apy, stochastic analysis has been employed in Jenkins et al. [81]
in order to evaluate the robustness of automated vs. manual plat-
forms. These techniques have not been explored in manufacturing
platform selection for large scale adherent cell therapy products.
This article builds upon the work published in Simaria et al.
[7], Hassan et al. [63], and Pereira Chilima et al. [77] and presents
an integrated approach to select the optimal manufacturing tech-
nology for the manufacture of MSC-products considering both
economic and operational elements using an advanced decisional
tool. This tool comprises a process economics model coupled with
models for brute force optimization, dynamic process scheduling,
robustness analysis and MADM.  This article also applies multi-
ple reimbursement strategies to hypothetical cell therapy products
with industrially relevant dose sizes, and identiﬁes scenarios where
commercial feasibility will be challenging due to economic and/or
operational bottlenecks. Furthermore, this study provides insights
on areas within the manufacturing process, for which additional
development would allow for commercial feasibility of MSC-based
cell therapy products.
2. Materials and methods
2.1. Tool description
2.1.1. Overview
This tool is composed of several different components: a
database, a bioprocess economics model, a brute-force optimiza-
tion algorithm, a robustness analysis model and a multi-attribute
analysis model (Fig. 1). When starting the simulation, the user
selects the scale and demand scenarios to be evaluated. For each
type of technology (e.g. multi-layer ﬂasks, stirred tank bioreac-
tor with microcarriers etc.), the information is retrieved from the
database by the bioprocess economics model and the optimal size
of the cell culture vessel is determined. The information contained
in the database is also used by the bioprocess economics model to
evaluate the costs associated with each manufacturing platform.
Brute-force optimization is used to run multiple scale-demand
scenarios through the bioprocess economics model and store the
relevant information (e.g. COG/million cells, COG/dose, FCI, number
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mig. 1. Schematic representation of the integrated bioprocess economics tool. Th
ptimization, a multi-attribute decision making tool and a Monte Carlo simulation 
f cell culture vessels used). During a robustness analysis, Monte
arlo simulation is used to perform a number iterations of these
ariables and measure the probability of different events occurring
e.g. probability of achieving target COG). Multi-attribute analysis
s used to select optimal manufacturing platforms by consider-
ng both quantiﬁed operational and economic characteristics these
latforms.
.1.2. Bioprocess economics model
The process economics model described in this article was
eveloped in Microsoft Excel (Microsoft
®
Corporation, Redmond,
A)  as it provides a user-friendly interface and can be easily
oupled with Visual Basic for Applications (VBA, Microsoft
®
Corpo-
ation, Redmond, WA). The economic parameters used to calculate
he total COG were both direct and indirect. The direct costs
ncluded in this analysis were: media, trypsin, QC and consumables
e.g. single-use cell culture vessels). The indirect costs used in this
nalysis were labour and depreciation costs. The expressions used
o evaluate both direct and indirect costs are summarised in Table 5.
osts that were not associated with the core manufacturing unit
perations, such as waste disposal costs, were not considered in
his analysis.
Additionally to the work published in Simaria et al. [7], this study
lso includes the downstream processing costs (DSP). These costs
ere computed using the same methodology described in Hassan
t al. [63]. In this article however, a single technology for cell recov-
ry and wash was used, the ﬂuidised bed centrifuge (FBC). Final
ll was modelled using an automatic ﬁll line, the Crystal
®
Px sys-
em (Aseptic Technologies) and cryopreservation using a controlled
ate freezer. The key economic input parameters are summarised
n Tables 3 and 4..1.3. Brute force optimization
This model was combined with a brute-force optimization
acro built using VBA. This was used to run rapidly several sce-l encompasses a database, a process economics model coupled with brute force
l.
narios through the process economic model, store the results for
each technology-commercialisation scenario and, select the most
cost-effective technology in each scenario.
2.1.4. Monte Carlo simulation
Monte Carlo simulations were built using @Risk
®
(Palisade
Corporation, Newﬁeld, NY), and coupled with the bioprocess
economics model. During simulations, multiple independent trian-
gular distributions of critical process variables such as process yield
and proliferation rate were introduced to the bioprocess economics
model. @Risk was  then used to perform 10,000 iterations of these
variables and measure the probability of different events occur-
ring (e.g. probability of achieving target COG). This same model
was employed in estimating the sensitivity of the desired metrics
(e.g. COG) to different process parameters (e.g. process yield), by
individually changing the value of such parameters by ±a selected
percentage and measuring the impact that this change has on the
COG.
2.1.5. Multi-attribute decision-making
A weighted sum method was employed to account for both the
operational and economic groups of attributes of different manu-
facturing technologies. The different attributes were ﬁrst ranked
according to their importance in the cell therapy ﬁeld (where a
higher rank was more beneﬁcial than a lower rank) and normalised
weights (Wi) were determined relative to the sum of the rankings
of all the attributes considered within either the operational or
economic attribute groups:
Wi = ri/
n∑
ri (10)i=1
where
Wi = the normalised weight of attribute i
ri = the importance ranking of category i
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For all operational attributes, a high score is desirable whilst for
the economic cost attributes (COG and FCI) a high value is unde-
sirable. To address this, the attribute values were standardised by
converting them into a common dimensionless scale from 0 to 1 as
follows:
Sij = (sij − siWorst)/ (siBest − siWorst) (11)
where
Sij = the standardised rating for technology j for attribute i
siMin = the worst outcome for attribute i
siMax = the best outcome for attribute i
The relative importance of the total weighted economic and
operational ratings was  varied using dimensionless combination
ratios, which add up to 1 so as to create scenarios where opera-
tional attributes were more important than the ﬁnancial attributes
and vice-versa. The overall aggregate score of the different tech-
nologies was then calculated by using the weighted sum method
as follows:
Saggrj = (RC1 ×
n∑
i=1
(Sopij Wi )) + (RC2 ×
n∑
i=1
(Seconij Wi)) (12)
where
Saggrj = the aggregate weighted score of technology j
RC1= the operational combination ratio
RC2= the economic combination ratio
2.2. Case study setup
2.2.1. Case study overview
The decisional tool described in Section 2.1 was  used in the case
study in order to assess the economic and operational beneﬁts of
different manufacturing platforms for the production of allogeneic
MSC-based cell therapy products. The bioprocess economics model
simulates each day of a single product facility operating 335 days a
year with two  annual maintenance shutdowns, one in the summer
and one in the winter. The manufacturing process modelled in this
article is based on a 21 day long cell culture process with 3 expan-
sion stages and with the ﬁnal cell harvest, wash, concentration and
formulation occurring on day 21(Table 3).
The annual demand for MSC-based products is likely to vary
according to the indication being targeted, for example, indications
such as chronic low back pain have lower dose sizes (∼107 cells)
[51,52], whilst other indications such as GvHD the dose require-
ment is much higher (∼108-109 cells per patient) [17,55–58,82].
Given the differences in annual demands of different MSC-based
cell therapy products, the tool was used to analyse the behaviour of
different manufacturing technologies across manufacturing scales
varying from 1 to 100 billion cells per batch and demands ranging
from 10 billion to 10,000 billion cells per year. This scale limit was
established in Hassan et al. [63] as the maximum number of cells
which the current technologies for cell wash and concentration can
process. A minimum and maximum number of batches per year
that can be processed in a single facility was established through
discussions with industry experts to be 10 and 100 respectively.
In Simaria et al. [7] a condition was  applied where microcarrier-
based cell culture was  only considered in scenarios where planar
platforms were infeasible due to capacity constraints, so as to
accommodate the fact that planar systems are well-established
technologies, and therefore preference would be given to them
when possible. In the case study described in this paper, however,
this assumption has been lifted in order to explore the cost-beneﬁt
of microcarrier-based cell culture at smaller manufacturing scales.
The planar technologies considered in this case study were
multi-layer ﬂasks (MLF) (e.g. Cell Factories
®
, CellSTACKs
®
), multi-
plate bioreactors (MPB) (e.g. Xpansion
®
), hollow ﬁbre bioreactors
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Table  4
General assumptions.
Category Parameter Value Unit
Scenario set up Max  number of batches 100 –
Min  nr of batches 10 –
Lang factor 23.67 –
Max  number of FBCs/batch 1 –
Depreciation period 7 Years
Mass balance Seeding density 4,000 Cells/cm2
Harvest density 45,000 Cells/cm2
Costs Trypsin 30 $/L
QC  10,000 $/batch
Media 450 $/L
Microcarrier costs 5 $/g
Biosafety cabinet 17,000 $/unit
Operator cost 120,000 $/year
Time  constraints Shift time 8 h
Gowning, documentation and cleaning time 20% of shift time
Maximum time allowed for expansion process setup (day 1) 6 h
Passage (days 7 & 14) 3 h
Media exchange (days 4, 10 &17) 6 h
Harvest (day 21) 3 h
Microcarrier removal, wash and concentration (day 21) 4 h
Vialling (day 21) 2 h
Table 5
Equations used to calculate COG.
Number Parameter Expression
1 Number of cell culture vessels per batch for
expansion stage n
Nnunit = ((Ncells/batch/ (yDSP × ycell detachment × ybatch sucess))/at )
2  Cell culture vessel area for microcarrier-based
cell culture
acell culture vessel = Densitymicrocarrier × Utilisationcell culture vessel × aper gram
3 Cell culture media costs across 3 expansion
stages
Cmedia =
∑n=3
n=1Cmedia/ml × N
n
unit × Vmedia/a × at × 2
4  Trypsin costs across 3 expansion stages Ctrypsin =
∑n=3
n=1Ctrypsin/ml × N
n
unit × Vtrypsin/a × at
5 Consumable costs Cconsumables =
∑n=3
n=1N
n
unit × Cconsumable/unit
6 Labour costs Clabour = Coperator × Rdocumentation/executing × Roverhead/operator × MAXday=335day 1
Stepn∑
Step 1
((tstep × Nnunit )/tstep max)
7  Fixed capital investment FCI = Cequipment × Lf
8 Equipment costs (minus biosafety cabinets) Cequipment =
equipment=n∑
equipment=1
Cequipmnet/unit × MAX(Nnunit/Capacityequipment )
9  Biosafety cabinet costs CBSC = CBSC/unit × MAX
{
day=335∑
(tstep × Nunit )/tstep max
}
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hhe deﬁnitions of the abbreviations used in the equations listed above can be found
HFB) (e.g. Quantum
®
) and the 3D technology considered was
ingle-use bioreactors with microcarriers in suspension in stirred
ank reactors (STR). The key characteristics of the different tech-
ologies are outlined in Table 3. The resource requirement, COG
nd major cost drivers of these manufacturing platforms were
dentiﬁed across different scales through a detailed process eco-
omics analysis. The cost-effectiveness of microcarrier-based cell
ulture was further investigated by evaluating the critical pro-
ess parameters which make 3D cell culture more attractive than
lanar technologies. The results from the process economics anal-
sis were used in the multi-attribute decision analysis where
oth operational and economic attributes of different manufac-
uring platforms were quantiﬁed. The robustness of the different
echnologies was also assessed at different manufacturing scales
hrough a Monte Carlo analysis. The process economics analysis
as placed in context by evaluating the commercial feasibility of
roducts manufactured using different technologies when current
eimbursement strategies are applied. This analysis identiﬁed sce-
arios where successful commercialisation is unfeasible due to
igh COG or capacity constraints resulting in failure to meet theday=1
pendix 1.
annual demand. These scenarios were further investigated through
an optimization analysis.
2.2.2. Process overview
The manufacturing process starts with cell culture assuming
that master cell banks are in place. Three cell culture stages were
modelled each lasting 7 days, making a total of 21 days of cell cul-
ture. During each cell culture stage a media exchange step was
performed such as to maintain nutrient concentration and hence
promote cell viability. The cells were seeded at 4,000 cells per cm2
and harvested at density of 45,000 cells per cm2 with a doubling
time of around 48 h.
The cell culture stage was  followed by cell wash and concen-
tration. Given that ﬂuidised bed centrifuge (FBCs) are expensive
(between £180,000–£500,000 [63]), and that it is impossible to
manufacture 100 batches of 21 days in series within a year, the
utilization of FBCs was maximised by staggering batches in parallel
such that cell wash and concertation took place on different days for
different batches being manufactured in parallel. The ﬁnal concen-
tration of the manufacturing process was  assumed to be 10 million
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Table  6
Assumptions for multi-attribute decision-making and stochastic cost analysis.
Attribute Ranka MLF  MPB HFB STR
MULTI-ATTRIBUTE DECISION-MAKING ANALYSIS
Operational parameters Ease development Tr(1,2.2,3) Tr(1,4,5) Tr(2,3.4,5) Tr(2,3.2,5) Tr(1,2.4,4)
Ease  of validation Tr(2,3.6,4) Tr(2,3.2,5) Tr(3,3.4,5) Tr(1,2.8,5) Tr(2,3,4)
Ease  of setup Tr(1,2.8,5) Tr(1,3.6,5) Tr(2,3,4) Tr(3,3.8,5) Tr(2,3,4)
Ease  of operation Tr(2,3.4,5) Tr(1,2.2,4) Tr(2,3.6,4) Tr(1,3.6,5) Tr(3,3.6,4)
Ease  of scale-up Tr(1,3.8,5) Tr(1,2.4,4) Tr(3,3.6,5) Tr(1,1.6,2) Tr(1,3.2,5)
Economic parameters COG/millionb ($) 2 Tr(25,78,435) Tr(21,46,99) Tr(85,163,351) Tr(10,37,10)
FCIb ($M) 1 55.7 19.8 81 21
ROBUSTNESS ANALYSIS
Cell detachment yield – Tr(0.85,0.9,0.95) Tr(0.85,0.9,0.95) Tr(0.85,0.9,0.95) Tr(0.6,0.75,0.9)
DSP  yield – Tr(0.58,0.68,0.78) Tr(0.58,0.68,0.78) Tr(0.58,0.68,0.78) Tr(0.512,0.612,0.712)
Batch success rate – Tr(0.9,0.95,0.97) Tr(0.93,0.95,0.98) Tr(0.93,0.95,0.98) Tr(0.93,0.95,0.98)
Doubling time (h) – Tr(32,34,37) Tr(33,34,35) Tr(33,34,35) Tr(32,34,37)
For the operational criteria, a higher score of 5 indicated the best technology in that particular criteria and a lower score of 1 indicated the worst technology.
Tr(a,b,c) refers to the triangular probability distribution where a, b, c are the minimum, most likely, and maximum values, respectively.
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pThe ranks and scores were attained from a survey distributed across industry e
lobal  product manager, vice president of technology and manufacturing, head of
igher  the rank the better the technology. A higher value of the rank indicated a cri
b COG and FCI are taken from a scenario with a batch size of 10 B cells per batch a
ells per ml.  These cells were then diluted in DMSO containing solu-
ion, placed in 6 ml  cryovials and cryopreserved using a controlled
ate freezer.
The labour requirement was evaluated by using the number
f operators per team of operators. The number of operators per
eam varies according to the manufacturing platform used, as these
equire different numbers of manipulations. For example, in open
rocessing using multi-layer ﬂasks, a higher number of manipula-
ions is required with respect to the use of automated bioreactors
nd therefore the number of operators per team is higher for these
echnologies.
The shift time applied here was 8 h, however, an assumption was
ade that only 80% of the shift time was spent in the cleanroom
nd the remaining 20% was used in gowning and de-gowning and
ocumentation.
.2.3. Key assumptions
Robustness analysis was performed using the Monte Carlo sim-
lation model described in Section 2.1. During this analysis, the
anufacturing process was ﬁxed and different critical process
arameters were varied such that the absolute COG remained
onstant whilst the throughput varied. Moreover an assumption
as made that in scenarios where the number of cells produced
xceeded the expected number of cells, these additional cells
ould still be commercialised and not wasted resulting in lower
OG/million cells in such scenarios.
The values used for the critical process variables were attained
hrough a series of discussions with industry experts. The ratio-
ale behind these assumptions is based on the fact that multi-layer
asks are manual systems and therefore prone to variability. This
as assumed to have an impact on the cell doubling time and batch
ailure rate due to the limited control over the process parame-
ers. Moreover, given that microcarrier-based cell culture is a more
ascent technique in the cell therapy ﬁeld, it was also assumed that
he variability in the proliferation rate of cells would also be higher
n these systems. The additional degree of difﬁculty in dissociat-
ng cells from microcarriers with respect to 2D technologies was
lso accounted for by allowing extra variability in cell detachment
fﬁciency in 3D cell culturing. Table 6 summarises the minimum,
aximum and most likely values of the parameters evaluated.
Multi-attribute analysis was performed in order to quantify bothperational and economic parameters. The scores for operational
ttributes were attained by distributing a survey questionnaire
cross multiple industry experts on their experience in designing a
rocess for commercial scale manufacture of cell therapy products.s in positions such as: senior pilot plant manager, business development manager,
ulture services of Eufets GmbH, Promethera, Pluristem and Pall Life Sciences. The
 of greater importance/weighting.
emand of 100 B cells per year.
In total, seven interviews were carried out with experts spanning
roles such as senior pilot plant manager, business development
manager, global product manager, vice president of technology and
manufacturing, and head of cell culture services across innovator
companies, contract manufacturers and vendors. The survey asked
them to rank operational categories according to their importance
and to rank different cell culture technologies on those categories.
The operational categories considered were ease of development,
ease of validation, ease of setup, ease of operation and ease of scale-
up. The actual development costs were not considered at this stage
but have been explored in parallel work by Hassan et al. [78]. The
scores used in this section were the average of the responses and are
summarised in Table 6. The scores from both economical categories
(FCI and COG/million cells) were gathered from the process eco-
nomics model. Here, an assumption was made that the COG/million
cells was  twice as important as the FCI costs, such that the long term
beneﬁts of using a particular technology would outweigh the initial
capital investment.
In this analysis, the capacity of the different manufacturing tech-
nologies for producing enough cells for different commercialisation
scenarios was  assessed. An assessment of the commercial feasibil-
ity of MSC-based cell products under the UK’s National Institute
of Health and Care Excellence (NICE) maximum reimbursement
limit (approximately $40,000 per quality adjusted life) [83] was
also carried out. This allowed for the identiﬁcation of scenarios
where commercial failure would occur due to capacity or economic
constraints.
In order to recommend possible process improvements to
overcome these challenges, a sensitivity analysis was  performed.
This analysis aimed at identifying the key factors contributing to
both economic and operational bottlenecks. During the sensitiv-
ity analysis cost parameters were varied by ± 25% and operational
parameters varied according to the minimum and maximum values
used in the robustness analysis (Table 6). The effect of varying these
factors on COG and throughput was measured and the factors with
the highest impact on the economic and operational performance
of MSC-based manufacturing processes were then used during the
optimization analysis, where target values for these factors were
recommended.
3. Results and discussionThis section summarises the key insights from the techno-
economic analysis of alternative cell culture technologies for
allogeneic MSC  therapies across different dose-demand scenarios.
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ar  b) Impact of different cost categories on COG with increasing demand and batc
ioreactors and STR = single use bioreactors with microcarriers.
he analysis identiﬁes key COG drivers, weighs up the ﬁnan-
ial and operational beneﬁts, and determines the robustness and
eimbursement potential of each technology. For scenarios where
roduct commercialisation was deemed infeasible, the key param-
ters which inﬂuence both cost-effectiveness and capacity were
dentiﬁed and optimised.
.1. Process economics analysis
.1.1. Deterministic cost comparison
The relative cost-effectiveness of different manufacturing plat-
orms is highly dependent on the scale and demand being explored
7]. This is illustrated in Fig. 2a, which shows the COG per million
ells proﬁle of the different technologies featured in this article
cross different annual demands and scales. At a smaller scale of
 billion cells per batch, planar platforms are more cost-effective
han 3D cell culture. When such small batch sizes are manufac-
ured in low frequency (10 times per year) such that indirect costs
ominate the overall COG, multi-plate bioreactors become the most
ost-effective option due to the low equipment costs and relatively
ow labour requirement. When the number of batches is increased
o 100, direct costs become the major cost driver, which causes
he optimal technology to shift to multi-layer ﬂasks; this is due to
he fact that these have considerably lower consumable costs with
espect to all other manufacturing platforms (Table 3). These sce-
arios can be translated into a process manufacturing 100 to 1,000facturing platform in each batch size-demand scenario is represented by a black
. Where MLF  = Multi-layer ﬂasks, MPB  = Multi-plate bioreactors, HFB = hollow ﬁbre
doses per year of an MSC  based treatment for heart disease with a
dose size of 100 million cells [17,55–58,82].
When increasing the scale to 10 billion cells per batch, reach-
ing demands of 1 trillion cells per year (10,000 doses per year
of a treatment for heart disease), the scalability of the different
manufacturing platforms determines their cost-effectiveness. High
scalability decreases the number of cell culture vessels used per
batch, and therefore decreases the requirement for equipment
and personnel. Hence, microcarrier-based cell culture becomes
the most cost-effective technology at both demands, 100 billion
and 1 trillion cells per year, with a very small economic advan-
tage with respect to multi-plate bioreactors ($21/million cells vs
$27/million cells). Increasing the scale further to 100 billion cells
per batch reaching high demands of up to 100,000 doses of 100
million cells per year, increases the importance of scalability, mak-
ing microcarrier-based cell culture signiﬁcantly more cost-effective
than all other technologies. Furthermore, in scenarios where the
market penetration increases over time, such that the production of
MSCs increases from low demands up to “blockbuster-like” quan-
tities being manufactured annually, microcarriers offer relatively
low COG across the different scales of production.
Fig. 2a portrays hollow ﬁbre bioreactors as the least cost-
effective technology across most scales and demands. These
bioreactors, offer superior operational features (Table 6), however,
the high consumable and equipment costs associated with this
technology (Table 2) do not allow this bioreactor to be ﬁnancially
competitive at commercial scale.
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.1.2. Factors affecting the cost-effectiveness of different
anufacturing technologies
Understanding of the key factors affecting the COG (e.g. media,
ell culture vessel, equipment etc.), is critical for effective process
ptimization. Since the impact of different process components on
OG/million cells varies with the scale and demand selected, Fig. 2b
llustrates the change in cost drivers across different scenarios.
The effect on COG/million was explored when: (1) increasing
he scale of production (from, 10 billion cells/batch to 100 bil-
ion cells/batch) while keeping the same annual demand (1 trillion
ells/year); (2) increasing the scale and annual demand (from 10
illion cells/batch and 1 trillion cells/year to 100 billion cells/batch
nd 10 trillion cells/year) while maintaining the same number of
atches per year (100); (3) increasing the annual production (from
 trillion cells/year to 10 trillion cells/year) while keeping the same
atch size (100 billion cells/batch) and increasing the number of
atches per year (from 10 batches/year to 100 batches/year).
) Scaling up from 10 billion cells per batch to 100 billion cells
per batch while keeping the same annual demand has a neg-
ative impact on the COG of all planar technologies. This is
attributed to capacity constraints in planar technologies; scaling
up means adding more cell culture vessels in parallel requir-
ing more equipment and personnel, and therefore, increasing
the depreciation and labour costs. Microcarrier-based cell cul-
ture on the other hand beneﬁts from high capacity, therefore
no increase in number of manipulations was seen. Furthermore
these bioreactors can handle larger numbers of cells with no
additional depreciation costs and using the same number of
operators reducing changes in COG with increasing scale. more cost-effective than planar technologies across multiple scales and demands,
ce area per litre for which single use bioreactors with microcarriers are more cost
cy of 75%. Min  and max  number of batches per year = 10 and 100 respectively.
2) Increasing the annual demand by keeping the same number of
batches and increasing the scale of manufacture increases the
number of aseptic manipulations, however, it has cost beneﬁts
across all technologies. Although the increase in scale was pre-
viously shown to increase the labour and depreciation costs in
planar technologies, these costs are now spread over a higher
number of cells resulting in an overall positive impact in the
COG/million cells. This positive impact is clearly seen in micro-
carriers where there is a dramatic drop in COG/million cells of
42% with the increase in scale causing cell culture media to be
the main cost driver.
3) Increasing the annual production by increasing the number of
batches per year and keeping the same batch size decreases the
COG/million further for all technologies as the indirect costs are
spread over more cells as seen in the previous point.
3.1.3. Critical parameters contributing to the cost effectiveness of
microcarrier-based cell culture
Microcarriers in single-use bioreactors are the most cost-
effective technology for the manufacture of adherent cell therapy
products with high annual demands (Fig. 2a). Since different micro-
carriers have different surface areas and will result in different cell
detachment yields [84], Fig. 3 illustrates the critical process param-
eters which allow for microcarrier-based cell processing to be more
cost-effective than planar technologies across different scales and
demands. In Fig. 3a, the efﬁciency in separating the cells from the
microcarriers (cell detachment yield) is varied, and the critical cell
detachment yield for which microcarriers are more cost-effective
than planar technologies is calculated. Fig. 3a shows that at small
scales of 1 billion cells per batch, where planar technologies are
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tig. 4. Labour utilization per day for cell culture, wash and formulation throughou
0  B cells and across multiple manufacturing platforms. The number of FTEs requir
here  MLF  = Multi-layer ﬂasks, MPB  = Multi-plate bioreactors, HFB = hollow ﬁbre b
ore cost-effective (Fig. 2a), the yield of the microcarrier-cell
etachment step must be increased from 75% to up to 85% in order
or these to be more cost-effective than planar technologies. Losses
n detachment yield can be minimised by using thermosensitive
icrocarriers or even avoided with injectable or dissolvable micro-
arriers. When using thermosensitive mircrocarriers, the cells can
e detached from the microcarriers by changing the temperature
nstead of using enzymes and thus this enhances the detachment
ield [85]. When using injectable microcarriers, no microcarrier
eparation step is required [86]. The use of injectable microcar-
iers will pose some regulatory implications as it will change the
roperties of the product. Moreover, the use of injectable micro-
arriers may  also affect the cryopreservation process. Additional
trategies to enhance the detachment yield include optimizing the
onditions for cell detachment (e.g. enzyme used, washing protocol,
ncubation time and temperature). As the scale increases, scalabil-
ty plays its part and microcarriers become more cost-effective than
lanar platforms, hence this critical cell detachment yield drops
igniﬁcantly to as low as 30%. Fig. 3 also shows that the manufac-
uring scale has a higher impact on the relative cost-effectiveness
f microcarrier-based cell culture than annual demand.
Fig. 3b explores the critical surface area per litre for which micro-
arriers are more cost-effective than planar technologies. Typical
alues for surface area per litre can vary from the 100′s cm/L to the
0,000′s cm2/L (Table 2) depending on the microcarrier of choice
nd its seeding density. This ﬁgure shows that at low scales of 1 bil-
ion cells per batch, the surface area per litre must be increased in
rder for microcarriers to be more cost-effective than planar tech-
ologies. Different strategies can be applied in order to increase the
urface area per litre of cell culture. These include increasing the
oncentration of microcarriers in cell culture and switching from a
on-porous to a porous microcarrier. If decantation is used to sep-
rate the cells from the microcarriers, adding more microcarriers
o the bioreactor may  increase the overall process time if the cellsﬁrst 50 days of the year, for a single product facility manufacturing 100 batches of
 each manufacturing platform is represented on the top right corner of each ﬁgure.
tors and STR = single use bioreactors with microcarriers.
settled around the beads are to be recovered through consecutive
dilution. Moreover, if ﬂuidised bed centrifugation is used for the
separation of microcarriers from the solution as was  assumed in
this article, a higher seeding concentration of microcarriers would
ﬁll the chambers of the FBC more rapidly requiring a higher number
of cycles, which also has a negative impact on the processing time.
Furthermore, switching to a porous microcarrier may alter the per-
formance of the process as cells may  grow differently depending on
the microcarrier surface and structure. As the scale increases, Fig. 3
shows that the ﬂexibility in surface area per litre also increases for
the reasons previously mentioned.
3.2. Operational characteristics of manufacturing platforms for
mesenchymal stem cell culture
3.2.1. Labour requirement
One of the key differences across the alternative technologies
used is the labour requirement. This parameter is related to the
number of manual operations required in the manufacturing pro-
cess. Fig. 4 shows the number of man  hours required to manufacture
100 batches of 50 billion cells. For greater resolution, the ﬁgure only
shows the ﬁrst 50 days of the year. The different batches are stag-
gered one day apart such that harvest occurs on different days for
each batch as previously described in Section 2.2. The manufactur-
ing process from cell culture to formulation occurs in 21 days. In
Fig. 4, seven batches are being manufactured in parallel in staggered
mode, and, the highest labour utilization occurs from day 14 to 24.
On the 14th day the passage to the last expansion stage (the stage
with the highest number of cell culture vessels per batch) is carried
out. The media exchange at the last expansion stage is carried out
on day 17 and harvest on day 21 (Table 4). As 7 batches are being
staggered, labour utilization is increased from day 14 to day 16 as
the ﬁnal passage is being carried out on 3 batches, from day 17 to
20 the other 4 batches are passaged, however, media exchange of
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Fig. 5. a) Sensitivity plots showing the economic attribute versus the operational attribute across different commercialisation scenarios. The y-axis represents the aggregate
score  between both attributes, where the optimal technology has the highest score. The x-axis, represents the weight of the economic attribute with respect to the operational
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ame  importance and on the right-hand-side the economic attribute has the highest
cenarios. Where MLF  = Multi-layer ﬂasks, MPB  = Multi-plate bioreactors, HFB = holl
he ﬁrst batch occurs on day 17 explaining the dramatic increase
n labour utilization. On day 21, all batches have been passaged but
he ﬁrst batch is being harvested and the last media exchange of
atch 5 is initiated, explaining the slight drop in labour utilisation.
inally on day 24, media exchange in the last expansion stage was
oncluded for all 7 batches, and the only operation taking place
s the harvest of batch 4 and therefore the number of man  hours
equired drops further and the cycle is repeated for the next set of
 batches.
Fig. 4 shows clearly that multilayer ﬂasks have relatively high
abour requirement. A similar trend in labour requirement would
e expected when using hollow ﬁbre bioreactors due to the fact that
hese also have limited capacity in comparison with multi-plate
ioreactors and single-use bioreactors with microcarriers (Table 3);
owever, the fact that hollow ﬁbre bioreactors are automated sys-
ems causes its labour requirement to be reduced. Microcarriers
n stirred tank bioreactors have high capacity and therefore only a
ingle bioreactor is used per batch reducing the number of manip-
lations required and hence reducing the number of operators
eeded.
.2.2. Multi-attribute decision-making
Additional to resource requirement, operational beneﬁts of
echnologies for adherent cell expansion also include: ease of devel-
pment, ease of validation, ease of setup and ease of operation.
he relative scores of the different manufacturing technologies in
ach of these categories are summarised in Table 6. The category
hich was voted to have the highest importance when selecting a
anufacturing technology was ease of scale-up. Table 6 also shows
hat processes using multi-layer ﬂasks are relatively easy to vali-he centre, where the weight of the economic attribute is 0.5, both attributes have the
rtance. b) COG per million cells distribution across two  different commercialisation
re bioreactors and STR = single use bioreactors with microcarriers.
date and develop but difﬁcult to operate and scale-up. Multi-plate
bioreactor-based processes are relatively easy to validate, are auto-
mated and easy to scale-up. These systems are however considered
relatively difﬁcult to setup with respect to hollow ﬁbre bioreac-
tors and multilayer ﬂasks. Hollow ﬁbre bioreactors are relatively
easy to setup and provide a high degree of automation, however,
these bioreactors pose challenges during scale-up. Microcarrier-
based cell culture is relatively easy to scale-up and it is a highly
automated platform; the challenges associated with this platform
include setting-up the bioreactor and developing the microcarrier-
based process.
Fig. 5a shows the weighted sum of the operational and economic
attributes of the technologies featured in this article across dif-
ferent commercialisation scenarios. This ﬁgure highlights that at
small scale-small demand combinations, for all values of the eco-
nomic combination ratio, multi-plate bioreactors have the highest
rank with the highest aggregate score. This is due to the fact that
these bioreactors have the highest overall operational score, and
that these are also the most cost-effective technology at 1 billion
cells per batch and 10 billion cells per year as seen in Fig. 2.
In the same scenario, the second optimal technology for all com-
bination ratios of economic features versus operational features are
single use bioreactors with microcarriers, and, although these have
a slightly lower operational score with respect to multi-layer ﬂasks,
they are far more cost-effective than these. This trend becomes
more evident as the combination ratio of the economic attribute
increases, resulting in a greater difference between the aggregate
scores of single use bioreactors with microcariers and multi-layer
ﬂasks. Fig. 2 illustrated that in small scale-small demand scenar-
ios, the decision between microcarriers and multi-plate bioreactors
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Table  7
Statistical data on COG/million cells and multi-attribute decision making analysis for the competing technologies for low and high demand scenarios.
Batch size: 1B cells per batch Demand: 10 B cells per year Batch size: 100 B cells per batch
Demand: 10,000 B cells per year
MLF  MPB  HFB STR MPB  STR
COG/million cells ($)
p(COG ≤ COGoptimal) (%) 20 50 5 45 15 45
Mean  347 224 342 238 17 13
Standard deviation 162 63 97 111 5 6
p-value N/A 2E-23 7E-19 4E-39 N/A 9E-119
Aggregate score
p(Aggregate score ≥ 0.5) (%) 25 80 50 70 25 80
Mean  0.26 0.89 0.32 0.68 0.59 0.69
Standard deviation 0.16 0.13 0.12 0.13 0.15 0.15
p-value N/A 1E-155 2E-58 4E-63 N/A 2E-85
N value o
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oote: The p-values were attained using a 2-tailed homoscedastic t-test with an alpha 
-values were derived using each of the technologies as the baseline for statistical 
he  p-values using one of the planar technologies as the baseline case as an illustra
s challenging as there is only a 10% difference in COG between
he two systems. Fig. 5a helps discriminate further between these
anufacturing platforms by reconciling economic and operational
eneﬁts with each. In this scenario, the multi-plate bioreactors have
he highest overall aggregate score and can hence be considered the
ptimal technology.
On the other hand, when the annual demand is increased to
0,000 billion cells in Fig. 5a, the technology rankings change.
t this higher scale, there are now only two manufacturing plat-
orms competing against each other, as the others lack the capacity
o fulﬁl such high scales. As previously mentioned, multi-plate
ioreactors have superior operational features with respect to
icrocarrier-based cell culture, however, when considering the
nancial attributes, the COG per million for these manufacturing
latforms is now $17.4 and $13.3 respectively resulting in a 30%
ifference. This causes the trends seen in Fig. 5a where, on the left
and side, where operational features are prioritized, multi-plate
ioreactors rank ﬁrst. This ranking slowly changes, and, in the mid-
le, when both economic and operational characteristics have the
ame importance, microcarrier systems take over as the optimal
anufacturing technology remaining in ﬁrst place as the priority is
hifted towards the economic beneﬁts. Fig. 5a shows that despite
he superior operational features of multi-plate bioreactors, scala-
ility is the most important parameter in large scale manufacture
f adherent cell therapy products (as shown in Table 6) and there-
ore microcarrier systems are the best technology to be used in such
cenarios.
.2.3. Robustness analysis
Process variability is another key operational parameter which
ay  affect the potential for commercial success of cell therapy pro-
esses, as failure to meet the demand will increase the COG/million
ells. Fig. 5b shows clearly the impact of the higher variabil-
ty of processes employing microcarriers and multi-layer ﬂasks
hrough wider COG distributions. Despite this fact, and although the
eterministic analysis portrays multi-plate bioreactors as the most
ost-effective technology in small scale scenarios, microcarriers
till have a similar probability of achieving the optimal COG/million
ells (lowest COG/million cells). This is due to the fact that the vari-
bility of the different parameters is both positive and negative and
he difference in COG between multi-plate bioreactors and stirred
ank bioreactors with microcarriers is small. Increasing the scale
nd demand decreases the probability of multi-plate bioreactors
chieving the minimal (optimal) COG/million cells and emphasises
hat, despite the uncertainties surrounding microcarrier systems,
hese are the optimal platform to be used for large scale production
f MSC-based cell therapy products.f 0.05. A p-value below 0.05 indicates a signiﬁcant difference between distributions.
cance testing; in all cases p-values below 0.05 were obtained and this table shows
Table 7 conﬁrms that although microcarriers have higher vari-
ability they still have the highest probability of achieving the
optimal COG/million cells at higher scales. The table also indi-
cates that at smaller manufacturing scales multi-plate bioreactors
have a slightly higher probability of being the technology with the
highest economic and operational aggregate score with respect to
microcarrier-based platforms, and as the scale increases, this trend
is altered as microcarriers have the highest aggregate score. All dis-
tributions were found to be signiﬁcantly different from one another
as indicated by all p-values being smaller than 0.05; an illustration
of these p-values is highlighted in Table 7 compared to the baseline
planar technology at low and high demands.
3.3. Performance targets for successful commercialisation
analysis
3.3.1. Reimbursement analysis
The reimbursement strategy to be applied to a product is a use-
ful parameter to establish manufacturing COG targets and may  vary
according to the indication, efﬁcacy of the treatment and country
of commercialisation. Fig. 6a shows the minimum selling price for
which the manufacturing COG is 40% or 15% of sales across multiple
commercialisation scenarios. COG as 40% sales has been established
to be the higher end of COG as % sales in allogeneic cell therapy
products, and 15% is a typical COG as % sales of small molecules
[87]. Fig. 6a shows that for a drug with low patient demand (100
patients per year), achieving COG as 40% sales with a selling price
of $40,000/dose will be challenging. Fig. 6a also shows that even
at high annual demands (10,000 patients/year) products with high
sizes (1 billion cells) will struggle to achieve COG as 15% sales as the
minimum COG as % sales achievable in such scenarios is 33%. More-
over, Fig. 6a also identiﬁes annual demands that are unachievable
due to the lack of capacity of current manufacturing technologies;
this is seen in high-dose high-demand scenarios. For example, with
the speciﬁcations applied to this case study for a size of 1 billion
cells it is challenging to achieve 100,000 doses/year as the maxi-
mum number of doses achievable is 60,000.
Fig. 6b shows the effect of process variability in the reim-
bursement strategy of cell therapy products for industry relevant
indications by evaluating the range in selling price required for COG
to be 15% sales. The indications considered were chronic discogenic
lumbar back pain, congestive heart and (GvHD) with dose sizes of
10 million, 100 million and 1 billion cells per dose respectively.
The reimbursement assumed for each different indication were
$1,200 (costs of caudal epidural injections, [88]), $40,000 (aver-
age myocardial regeneration reimbursement, [46]) and $107,000
(extracorporal photopherisis for GvHD, [89]) respectively.
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Fig. 6. a) Minimum selling price across multiple dose size and demands for which COG is 40% and 15% of sales when the minimum COG/dose across the different manufacturing
platforms is applied. The dashed line represents the current reimbursement from the NICE. b) Minimum selling price distribution for which COG is 15% of sales. For an annual
demand of 10,000 patients per year and for indications with different dose sizes and reimbursement strategies. The dashed line on each graph represents the typical
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Fig. 6b shows that for an MSC-based cell therapy product with a
ose size of 10 million cells per patient, COG as 15% sales could be
chieved under the current NICE reimbursement per QALY with
ny technology. However, when the reimbursement applied to
hronic discogenic lumbar back pain is used in this scenario, an
SC-based cell therapy product would struggle to be competitive
ith current treatments, as these are more cost-effective. For an
ndication requiring a higher dose size of 100 million cells such
s congestive heart failure, most manufacturing platforms would
atisfy the COG as % sales target under the current reimbursement
or congestive heart failure which coincides with the current NICE
eimbursement. Higher reimbursements may  be considered as
ome of these treatments may  replace the requirement for a heart
ransplant which are priced up to $500,000 [75]. Furthermore, com-
aring the NICE reimbursement with the reimbursement applied
n Heartcelligram-AMI
®
(Pharmicell, South Korea) an autologous
SC-based cell therapy product for post-myocardial infraction
hich is priced at $19,000 per dose [90], it is clear that current
rocesses for the manufacture of MSC-based products shown in
ig. 6b will struggle even more to reach commercial success.
A further increase in dose size to 1,000 million cells will narrow
own the choices in technology availability for MSC  cell culture,
s only multi-plate bioreactors and microcarrier systems are able
o satisfy such high scales of production. Moreover, none of these
latforms would be able to achieve satisfactory COG as % sales
nder current NICE reimbursement. Furthermore, even when the
ypical reimbursement with similar dose size is applied (GvHD),
ulti-plate bioreactors are not able to meet the target COG as %
ales and microcarrier systems would struggle to do the same.
®hen applying the reimbursement applied to Temcel (Mesoblast,
ustralia) an allogeneic MSC-based product targeted at GvHD with
 dose size of 1.2–1.7 billion cells resulting in a selling price of
117,983–$167,143 per dose ($7,079 per 72 million cells) [91], iti-plate bioreactors, HFB = hollow ﬁbre bioreactors and STR = single use bioreactors
is clear that even at this higher selling price, both manufacturing
platforms will struggle to meet the target COG as % of sales.
3.3.2. Sensitivity analysis
In order to understand the direction in which the development
effort should be focused, so as to address both the gross margin
limitations, and the capacity constraints mentioned in Fig. 6, a
sensitivity analysis was  performed. The manufacturing platform
used in this analysis is the single use bioreactor with microcar-
riers, as this is the most cost-effective technology to be used in a
high demand scenario such as this (Fig. 2). Fig. 7 indicates that the
factors that have the greatest impact on COG  at high dose size-
high annual demand scenarios are mostly operational since these
will ultimately inﬂuence the cell quantities which are produced per
batch. The factor with the highest impact on the COG is the cell dou-
bling time, this is attributed to the fact that this is a crucial factor in
determining the number of cells required from the beginning of the
process to meet a particular batch size due to the model set up. A
higher cell doubling time would mean a slower process, and hence
more cells would be required at the beginning of the cell culture.
This would increase the size of the cell culture vessels required dur-
ing the initial cell culture stages since more cells are being loaded
into them, increasing the resource requirement and hence the COG.
The nature of this scenario explains the asymmetry seen in the
impact of operational parameters on COG in Fig. 7. At the last expan-
sion stage of the chosen scenario, a single use bioreactor of 1,000 L
is being utilised at 60% capacity. Given that the full capacity of this
bioreactor is not being utilised, when the DSP or cell detachment
yield are decreased to 75% of their initial value, there is no signif-
icant change in COG since the same bioreactor can accommodate
the additional cells required to make up for the lower yields. When
the opposite occurs, and the DSP yield and cell detachment yield
are adjusted to 125% of their original value, the number of cells
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Fig. 7. Sensitivity analysis showing the impact of varying both process parameters and cost parameters by ± 25% with the exception of the batch success rate (varied by ± 5%
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fince  the base case is 95%). This ﬁgure shows the effect of process and economic pa
emand  of 10,000 cells per patient.
equired to meet the batch size decreases such that a 500 L biore-
ctor becomes optimal. Fig. 7 conﬁrms the conclusion drawn from
ig. 2b, where the cost parameter with the greatest impact on the
otal COG in large scale scenarios is the media costs.
Fig. 7 also highlights the considerable impact that the cell dou-
ling time has on the productivity of a cell therapy processes. In
his ﬁgure, the capacity of the single use bioreactor (surface area
er litre) was not varied, as this parameter has no bearing on the
umber of cells produced. The number of cells initially loaded into
he process, the DSP yield and the cell detachment efﬁciency were
aried by ± 25% of the base case instead. As expected, increasing
ny of these parameters by 25% increases the number of maximum
oses produced by 25%.
.3.3. Optimization case study
Having identiﬁed the key parameters affecting the proﬁtability
nd capacity of technologies for adherent cell culture, this section
ill determine the development effort required to overcome cur-
ent process and economic challenges.
Fig. 8 shows how varying the different parameters highlighted
y the sensitivity analysis affects the COG as % sales for a selling
rice of $40,000. The base case scenario presented in this ﬁgure
hows that in order to achieve COG as 15% sales, the surface area
er litre inside the bioreactor must be at least 20,000 cm2. If the cell
oubling time is decreased (Scenario 2), the COG as 15% sales target
an be reached by almost doubling the current bioreactor capacity
5,540 cm2 per litre) to 10,000 cm2 per litre in combination with
ncreasing the detachment yield from 75% to 100%. Solutions for
ncreasing the detachment yield have previously been discussed in
ection 3.1. The same COG target can be achieved without changing
he proliferation rate of the cells if the DSP yield can be enhanced
rom 61 to 81% (Scenario 4). The DSP yield is a combination ofers on the COG and throughput of an MSC  product with dose size of 1 B cells and a
microcarrier removal, cell wash, concentration and cryopreserva-
tion yields, with the values of 90%, 85% and 80% [63,91] respectively.
In this analysis, an assumption was  made that the FBC would be
used to remove the microcarriers from the cell containing solu-
tion. An alternative way  to increase the yield of this step is the
employment of the harvestainerTM (Thermoscientiﬁc, Waltham,
MA,  USA) technology instead of the FBC system for microcarrier
removal. Another alternative to increase the overall DSP yield is to
use a different cryoprotectant to DMSO in order to decrease cell loss
during cryopreservation [92,93]. Moreover, additional strategies to
increase the DSP yield include decreasing the concentration of the
cryoprotectant used and optimizing freezing process.
Fig. 9 shows how varying the key parameters which inﬂuence
the productivity of a manufacturing process for MSCs affects its
ability to achieve 100,000 doses per year of 1billion cells. Fig. 9
shows that the process throughput is dependent on the DSP yield,
and, that the maximum number of doses achievable across all sce-
narios is 75,600. This target is only achievable if the DSP yield is
increased to 81% (Scenario 3 & 5). Fig. 9 also shows that excessively
increasing the number of cells initially added to the process under
the base case detachment yield would not increase productivity;
although this would result in a higher number of cells achieved
during the expansion process, the maximum capacity of a single
FBC system under 4 h is ∼1 trillion cells, which translates into 1.8
billion cells initially added to the process. Furthermore, Fig. 9 shows
that the capacity of current DSP technologies is the key obstacle to
commercial scale manufacture of MSC-based cell therapy products.
Moreover, improving the performance of these technologies will
result in lower COG as COG decreases with increasing scale, hence
the development effort should be shifted towards the downstream
process.
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Fig. 8. Measurement of the impact of different parameters on the ability of reaching COG as 15% sales for a selling price of $40,000 per dose, an annual demand of 10,000
doses  and a dose size of 1 billion cells. The shaded are represents scenarios where COG as 15% sales is reached. A = discount on media costs, B = cell doubling time and C = DSP
yield.
Fig. 9. Measurement of the impact of different parameters on the ability of reaching 100,000 doses per year of 1 billion cells. A = Cell doubling time. B = Batch success rate;
C  = DSP yield.
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. Conclusion
This study has explored the economic and operational perfor-
ance of four candidate technologies for the commercial scale
xpansion of MSCs in order to evaluate the probability of each
f these technologies leading to a feasible business model. The
esults show that from an economic perspective, planar manufac-
uring platforms are most cost-effective at smaller scales (≤ 1B
ells/batch) whilst microcarrier systems are more cost-effective
t medium to large scales (10-100B cells/batch). The results have
evealed that for applications with low dose sizes (10 million cells),
he COG/dose vary between $485 and $1750 and for applications
ith high dose sizes (1 billion cells), the COG/dose vary between
13,134 and $111,488 depending on the technology and manu-
acturing scale selected. The results also show that the superior
perational characteristics of multi-plate bioreactors allows them
o closely compete with microcarrier systems even at larger scales.
owever, ultimately, microcarriers are the optimal technology for
arge-scale expansion of allogeneic MSC-based cell therapy prod-
cts. Furthermore, this study highlights that in order to achieve
ommercial success under current reimbursement strategies sig-
iﬁcant improvement is required in the sector for treatments with
arge dose sizes and that the market penetration of certain indi-
ations is limited by the capacity of the current technologies. This
tudy has also shown that future resources for the development
f technologies for commercial scale manufacture of cell therapy
roducts should be focused on DSP technologies. This tool can
e used to understand and quantify the current limitations and
haracteristics of the different technologies for mesenchymal cell
xpansion and can be extended to explore further options such as
he use of cultures based on aggregates or spheroids. Such analy-
es help predict the minimum reimbursement levels for different
SC-based cell therapy products that allow for feasible business
odels.
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ppendix 1.
n
unit Number of cell culture vessels required for the expansion
stage n0
cells/batch Number of cells produced per batch
DSP DSP yield
cell detachment Cell detachment yield
batch sucess Batch success rate
t Surface area for cell growth of a cell culture vessel
ensitymicrocarrier Microcarrier’s seeding density
tilisationcell culture vessel % utilization a cell culture vessel
per gram Surface area per gram of microcarrier
media Media costs
media/ml Media costs per ml
media/a Volume of media required per unit surface are of cell cul-
ture vesselineering Journal 137 (2018) 132–151
Ctrypsin Trypsin costs
Ctrypsin/ml Trypsin costs/ml
Vtrypsin/a Volume of trypsin required per unit surface are of cell
culture vessel
Cconsumables Consumables costs
Cconsumable/unit Consumables costs per cell culture vessel
Clabour Labour costs
Coperator Operator salary
Rdocumentation/executing Ratio between the documentation operator
and the executing operator
ROverhead/operator Ratio between labour overheads and operator
salary
tstep Time required per cell culture vessel to perform a partic-
ular activity
tstepmax Maximum time allowed for a particular activity
FCI Fixed capital investment
Cequipment Equipment costs
Lf Lang factor
Cequipmnet/unit Unit costs for a particular type of equipment
Capacityequipment Max  number of cell culture vessels that the
equipment can handle
CBSC Biosafety cabinet costs
CBSC/unit Biosafety cabinet costs per unit
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